Loading...
Healthcare

Indonesia Targets Global Pregnancy Supplement Market With 2.9 Billion MMS Tablets

16 Nov, 2026
Indonesia Targets Global Pregnancy Supplement Market With 2.9 Billion MMS Tablets

Indonesia is strengthening its domestic pharmaceutical industry by launching locally produced Multiple Micronutrient Supplements (MMS) for pregnant women, with eight pharmaceutical companies reaching a combined production capacity of 2.9 billion tablets annually. The initiative aims to reduce import dependence and position Indonesia as a supplier to the global pregnancy supplement market, which is estimated to require 36 billion tablets annually (15/11).

Indonesia Strengthens Domestic MMS Production to Reduce Imports

The Ministry of Health officially launched domestically produced MMS in Jakarta on November 15, 2026. The initiative is part of the government's efforts to increase local pharmaceutical production and reduce reliance on imported health products.

Health Minister Budi Gunadi Sadikin said the national pharmaceutical industry should prioritize medicines and supplements that are widely consumed by the public. He emphasized that domestic production could help keep economic activity, gross domestic product (GDP) contributions, and job creation within Indonesia.

"I have asked the Director General of Pharmaceuticals and Medical Devices to prioritize products that are most widely used by the public. If possible, we should avoid imports so that economic activity, gross domestic product (GDP), and job creation take place domestically," Budi said after the launch during the soft opening of the 2026 Health Innovation Festival (HAI Fest) at Balai Kartini, Jakarta.

Local MMS Production Capacity Exceeds Domestic Demand

Indonesia has an estimated 4.8 million to 4.93 million pregnant women each year. Each woman requires at least 180 MMS tablets over six months of pregnancy, bringing estimated domestic demand to between 860 million and 882 million tablets annually.

Currently, eight Indonesian pharmaceutical companies produce MMS, with a combined annual capacity of 2.9 billion tablets. This is approximately 3.4 times higher than domestic demand.

Budi said local manufacturers should not be concerned about potential overcapacity because international demand remains substantial. He also highlighted Indonesia's competitive labor costs compared with established producers such as the United States and Denmark.

"Indonesia has a competitive advantage because our labor costs are much more competitive than those in the United States and Denmark. Our products will certainly be cheaper and are very ready to compete for a share of the global market," Budi said.

Beyond MMS, the government is also encouraging domestic production of healthcare products that currently depend entirely on imports. These include blood plasma-derived products such as albumin, intravenous immunoglobulin (IVIG), and other related products.

Global MMS Demand Reaches 36 Billion Tablets Annually

Based on global projections of approximately 200 million births each year, worldwide MMS demand is estimated to reach 36 billion tablets annually.

UNICEF estimates that demand from low-income and lower-middle-income countries, particularly in Asia and Africa, will reach 16.02 billion tablets annually by 2030.

However, the number of countries currently producing MMS remains limited. The United States, Denmark, and Bangladesh are among the countries identified as existing producers.

Indonesia also has potential markets in neighboring countries. Cambodia requires approximately 72 million MMS tablets annually, while the Philippines needs around 252 million tablets per year.

These figures are part of the market opportunity highlighted by the Ministry of Health as Indonesian pharmaceutical companies expand their production capacity.

MMS Program Supports Maternal and Child Health

The domestic MMS launch was part of the 62nd National Health Day commemoration and resulted from collaboration between the Ministry of Health's Directorate General of Pharmaceuticals and Medical Devices and the Directorate General of Primary and Community Health.

According to L. Rizka Andalusia, Director General of Pharmaceuticals and Medical Devices, the collaboration aims to accelerate stunting reduction by improving maternal nutrition during pregnancy.

The government started its MMS supplementation program for pregnant women in 2024, covering 15 provinces and 209 districts and cities. The program received support from Vitamin Angels through a grant of 234 million tablets annually during the 2024–2026 period.

Evaluation results showed that 72% of pregnant women accepted and consumed MMS. This was higher than the 44.2% compliance rate recorded for iron and folic acid supplements, known locally as Tablet Tambah Darah (TTD).

Rizka explained that domestically produced MMS follows the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) standard formula. It contains 10 vitamins and five minerals to meet the micronutrient needs of pregnant women more comprehensively than TTD, which contains iron and folic acid.

"Various scientific studies show that MMS has the potential to reduce the risk of low birth weight (LBW) by 13% to 19%," Rizka explained.

Eight Local Manufacturers Develop MMS for Global Procurement

Of the eight Indonesian pharmaceutical companies capable of producing MMS, three products have already been listed in the government's procurement catalog and comply with UNIMMAP standards.

Meanwhile, two domestic pharmaceutical companies are participating in the global procurement process through UNICEF.

The Ministry of Health expects the development of domestic MMS production to strengthen national manufacturing independence, maintain supply sustainability, and improve the resilience of Indonesia's pharmaceutical industry.

The initiative is also expected to support improvements in maternal and child health in Indonesia.

"Through this launch, we hope to establish an important milestone in strengthening production independence, ensuring supply sustainability, and improving the resilience of the national pharmaceutical industry, while also supporting improvements in the health quality of Indonesian mothers and children," Rizka concluded.



PHOTO: MINISTRY OF HEALTH

This article was created with AI assistance.

*We make every effort to ensure the accuracy of our content, some information may be incorrect or outdated. Please let us know of any corrections at [email protected].

Read More

Please log in to post a comment.

Leave a Comment

Your email address will not be published. Required fields are marked *

1 2 3 4 5